Cure8 research brief
People with IBD are at higher risk for colorectal cancer; identifying stromal genes that track inflammation-driven EMT could help researchers find biomarkers or targets that explain how chronic inflammation promotes malignant transformation.
Researchers studying IBD-to-CRC progression, translational scientists focused on tumor microenvironment and biomarkers, and clinicians interested in research advances linking inflammation to cancer risk.
The authors mined existing single-cell RNA-seq datasets from intestinal biopsies and integrated those results with Cancer Genome Atlas bulk data and pharmacogenomic cohorts to follow stromal programs from healthy tissue through IBD to CRC.
ARHGEF15 was highlighted as enriched in a specific stromal/perivascular cell population and its expression correlated with EMT-related activity and worse survival in CRC cohorts.
These results point to ARHGEF15 as a candidate stromal biomarker for inflammatory EMT and stromal–immune remodeling during the IBD-to-CRC transition, but the work is retrospective and computational: prospective experimental and clinical validation is needed before clinical use or prognostic claims can be made.
Findings are retrospective and computational (reanalysis of published datasets). Prospective experimental and clinical validation is required before ARHGEF15 could be considered a prognostic marker or therapeutic target.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
New or improved fluorescent probes could enable more sensitive, noninvasive imaging of biochemical changes in the gut, which may aid research, earlier diagnosis, or monitoring of IBD and colorectal cancer.
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
